Cargando…
Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress
Nivolumab, formulated in the medicine Opdivo(®) (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or u...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025134/ https://www.ncbi.nlm.nih.gov/pubmed/35456527 http://dx.doi.org/10.3390/pharmaceutics14040692 |
_version_ | 1784690793053683712 |
---|---|
author | Torrente-López, Anabel Hermosilla, Jesús Salmerón-García, Antonio Cabeza, José Navas, Natalia |
author_facet | Torrente-López, Anabel Hermosilla, Jesús Salmerón-García, Antonio Cabeza, José Navas, Natalia |
author_sort | Torrente-López, Anabel |
collection | PubMed |
description | Nivolumab, formulated in the medicine Opdivo(®) (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo(®)) demonstrated stability up to 60 °C (1 h). As regards functionality all the nivolumab (Opdivo(®)) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses. |
format | Online Article Text |
id | pubmed-9025134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90251342022-04-23 Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress Torrente-López, Anabel Hermosilla, Jesús Salmerón-García, Antonio Cabeza, José Navas, Natalia Pharmaceutics Article Nivolumab, formulated in the medicine Opdivo(®) (10 mg/mL), is a therapeutic monoclonal antibody (mAb) used in the treatment of different types of cancer. Currently, there is insufficient knowledge about the behaviour of this protein with regards to the risk associated with its routine handling or unintentional mishandling, or when subjected to stress conditions in hospitals. These conditions can be simulated in forced degradation studies, which provide an in-depth understanding of the biophysical and biochemical properties of mAbs. In this study, we carried out a physicochemical and functional characterisation of nivolumab, which was subjected to various stress conditions: heat, freeze/thaw cycles, agitation, light exposure and high hypertonic solution. We used a wide range of analytical techniques: Far-UV CD, IT-FS, DLS, SE/UHPLC(UV)-[Native]MS, and ELISA. The results show that exposure to light was the stress test with the greatest impact on the samples, revelling the formation of non-natural dimers and a different isoform profile. In addition, nivolumab (Opdivo(®)) demonstrated stability up to 60 °C (1 h). As regards functionality all the nivolumab (Opdivo(®)) stressed samples were found to be stable except for those subjected to light and agitation, and to a lesser extent, those subjected to FTC 5 and NaCl stresses. MDPI 2022-03-23 /pmc/articles/PMC9025134/ /pubmed/35456527 http://dx.doi.org/10.3390/pharmaceutics14040692 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Torrente-López, Anabel Hermosilla, Jesús Salmerón-García, Antonio Cabeza, José Navas, Natalia Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress |
title | Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress |
title_full | Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress |
title_fullStr | Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress |
title_full_unstemmed | Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress |
title_short | Comprehensive Analysis of Nivolumab, A Therapeutic Anti-Pd-1 Monoclonal Antibody: Impact of Handling and Stress |
title_sort | comprehensive analysis of nivolumab, a therapeutic anti-pd-1 monoclonal antibody: impact of handling and stress |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025134/ https://www.ncbi.nlm.nih.gov/pubmed/35456527 http://dx.doi.org/10.3390/pharmaceutics14040692 |
work_keys_str_mv | AT torrentelopezanabel comprehensiveanalysisofnivolumabatherapeuticantipd1monoclonalantibodyimpactofhandlingandstress AT hermosillajesus comprehensiveanalysisofnivolumabatherapeuticantipd1monoclonalantibodyimpactofhandlingandstress AT salmerongarciaantonio comprehensiveanalysisofnivolumabatherapeuticantipd1monoclonalantibodyimpactofhandlingandstress AT cabezajose comprehensiveanalysisofnivolumabatherapeuticantipd1monoclonalantibodyimpactofhandlingandstress AT navasnatalia comprehensiveanalysisofnivolumabatherapeuticantipd1monoclonalantibodyimpactofhandlingandstress |